To evaluate the efficacy and safety of a fixed-dose, single-capsule budesonide(400µg)-formoterol(12µg) combination, in comparison with budesonide alone, both delivered via a dry powder inhaler, in 181 patients with uncontrolled asthma.This was Randomized, double-blind, multicenter, phase III, parallel clinical trial.

the age of the patients ranged from 18 to 77 years. After a run-in period of 4 weeks, during which all of the patients received budesonide twice a day, they were randomized into one of the treatment groups for 12 weeks, twice a day.

The primary outcome measures were FEV1, FVC and morning PEF. We performed an intention-to-treat analysis of the data.

Inclusion Criteria:

• Diagnosis of uncontrolled asthma
• Age ranged from 18 to 77 years
• Nonsmokers

Exclusion Criteria:

• Use of oral corticosteroids, anti-leukotrienes, immunoglobulins, beta blockers, digitalis, amiodarone, antifungals, antidepressants, monoamine oxidase inhibitors and tricyclics during the standardization
• Atrial fibrillation, Flutter, severe and complex tachyarrhythmias atrioventricular block 1,2 and 3
• Diabetes mellitus
• Pregnancy
• Neuropsychiatric diseases
• Pulmonary malformations, tuberculosis, Cystic fibrosis
• Immunosuppressive treatment
• Hospitalization for asthma or respiratory infection in last 30 days
• Severe systemic disease